Niagen Bioscience (NAGE) Change in Receivables (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Change in Receivables data on file, last reported at $3.4 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $3.4 million, up 267.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (up 386.87% YoY), and the FY2025 annual result was $756000.0, down 40.89% from the prior year.
• Change in Receivables grew to $3.4 million in Q1 2026 per NAGE's latest filing, from $1.3 million in the prior quarter.
• Over five years, Change in Receivables peaked at $3.8 million in Q4 2022 and troughed at -$2.7 million in Q2 2023.
• A 5-year average of $383000.0 and a median of $522000.0 in 2022 frame the typical range for Change in Receivables.
• On a YoY basis, Change in Receivables climbed as much as 2802.31% in 2022 and fell as far as 251.76% in 2022.
• A 5-year view of Change in Receivables shows it stood at $3.8 million in 2022, then sank by 109.22% to -$348000.0 in 2023, then sank by 84.48% to -$642000.0 in 2024, then jumped by 296.57% to $1.3 million in 2025, then soared by 170.36% to $3.4 million in 2026.
• Business Quant data shows NAGE's Change in Receivables at $3.4 million in Q1 2026, $1.3 million in Q4 2025, and -$1.2 million in Q3 2025.